FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 Glioblastoma Study Highlights Sex Differences in Brain Cancer January 30, 2019 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Is CBD Safe for People With Cancer? September 22, 2020 Load more HOT NEWS EMA Recommends Additional Extensions of Indications for Pembrolizumab Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... Should People Over Age 75 Be Screened for Colorectal Cancer? EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib
